Amgen Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Amgen Inc. (AMGN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $165.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- Amgen Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $165.00M, a 5.10% increase year-over-year.
- Amgen Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $75.00M, a 11.76% decline year-over-year.
- Amgen Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $125.00M, a 6.72% decline year-over-year.
- Amgen Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $127.00M, a 6.62% decline year-over-year.
- Amgen Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $494.00M, a 6.79% decline from fiscal 2024.
- Amgen Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $530.00M, a 16.74% increase from fiscal 2023.
- Amgen Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $454.00M, a 8.35% increase from fiscal 2022.
- Amgen Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $419.00M, a 16.07% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $165.00M 10-Q · filed 2026-08-05 | $240.00M 10-Q · filed 2026-08-05 | $365.00M derived: sum of 3 quarters · filed 2026-08-05 | $492.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $75.00M 10-Q · filed 2026-05-01 | $200.00M derived: sum of 2 quarters · filed 2026-05-01 | $327.00M derived: sum of 3 quarters · filed 2026-05-01 | $484.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $125.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $252.00M derived: sum of 2 quarters · filed 2026-02-13 | $409.00M derived: sum of 3 quarters · filed 2026-08-05 | $494.00M 10-K · filed 2026-02-13 |
| 2025-09-30 | $127.00M 10-Q · filed 2025-11-05 | $284.00M derived: sum of 2 quarters · filed 2026-08-05 | $369.00M 10-Q · filed 2025-11-05 | $503.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $157.00M 10-Q · filed 2026-08-05 | $242.00M 10-Q · filed 2026-08-05 | $376.00M derived: sum of 3 quarters · filed 2026-08-05 | $512.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $85.00M 10-Q · filed 2026-05-01 | $219.00M derived: sum of 2 quarters · filed 2026-05-01 | $355.00M derived: sum of 3 quarters · filed 2026-05-01 | $512.00M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $134.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $270.00M derived: sum of 2 quarters · filed 2026-02-13 | $427.00M derived: sum of 3 quarters · filed 2026-02-13 | $530.00M 10-K · filed 2026-02-13 |
| 2024-09-30 | $136.00M 10-Q · filed 2025-11-05 | $293.00M derived: sum of 2 quarters · filed 2025-11-05 | $396.00M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $157.00M 10-Q · filed 2025-08-06 | $260.00M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $103.00M 10-Q · filed 2025-05-02 | |||
| 2023-12-31 | $454.00M 10-K · filed 2026-02-13 | |||
| 2023-09-30 | $124.00M 10-Q · filed 2024-10-31 | $243.00M derived: sum of 2 quarters · filed 2024-10-31 | $290.00M derived: sum of 3 quarters · filed 2024-10-31 | |
| 2023-06-30 | $119.00M 10-Q · filed 2024-10-31 | $166.00M derived: sum of 2 quarters · filed 2024-10-31 | ||
| 2023-03-31 | $47.00M 10-Q · filed 2024-10-31 | |||
| 2022-12-31 | $419.00M 10-K · filed 2025-02-14 | |||
| 2022-09-30 | $121.00M 10-Q · filed 2023-10-31 | $241.00M derived: sum of 2 quarters · filed 2023-10-31 | $319.00M derived: sum of 3 quarters · filed 2023-10-31 | |
| 2022-06-30 | $120.00M 10-Q · filed 2023-10-31 | $198.00M derived: sum of 2 quarters · filed 2023-10-31 | ||
| 2022-03-31 | $78.00M 10-Q · filed 2023-10-31 | |||
| 2021-12-31 | $361.00M 10-K · filed 2024-02-14 | |||
| 2021-09-30 | $111.00M 10-Q · filed 2022-11-04 | $211.00M derived: sum of 2 quarters · filed 2022-11-04 | $268.00M derived: sum of 3 quarters · filed 2022-11-04 | |
| 2021-06-30 | $100.00M 10-Q · filed 2022-11-04 | $157.00M derived: sum of 2 quarters · filed 2022-11-04 | ||
| 2021-03-31 | $57.00M 10-Q · filed 2022-11-04 | |||
| 2020-12-31 | $349.00M 10-K · filed 2023-02-09 | |||
| 2020-09-30 | $109.00M 10-Q · filed 2021-11-03 | $210.00M derived: sum of 2 quarters · filed 2021-11-03 | $262.00M derived: sum of 3 quarters · filed 2021-11-03 | |
| 2020-06-30 | $101.00M 10-Q · filed 2021-11-03 | $153.00M derived: sum of 2 quarters · filed 2021-11-03 | ||
| 2020-03-31 | $52.00M 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $323.00M 10-K · filed 2022-02-16 | |||
| 2019-09-30 | $108.00M 10-Q · filed 2020-10-29 | $205.00M derived: sum of 2 quarters · filed 2020-10-29 | $269.00M derived: sum of 3 quarters · filed 2020-10-29 | |
| 2019-06-30 | $97.00M 10-Q · filed 2020-10-29 | $161.00M derived: sum of 2 quarters · filed 2020-10-29 | ||
| 2019-03-31 | $64.00M 10-Q · filed 2020-10-29 | |||
| 2018-12-31 | $327.00M 10-K · filed 2021-02-09 | |||
| 2018-09-30 | $94.00M 10-Q · filed 2019-10-30 | $187.00M derived: sum of 2 quarters · filed 2019-10-30 | $248.00M derived: sum of 3 quarters · filed 2019-10-30 | |
| 2018-06-30 | $93.00M 10-Q · filed 2019-10-30 | $154.00M derived: sum of 2 quarters · filed 2019-10-30 | ||
| 2018-03-31 | $61.00M 10-Q · filed 2019-10-30 | |||
| 2017-12-31 | $347.00M 10-K · filed 2020-02-12 | |||
| 2016-12-31 | $342.00M 10-K · filed 2019-02-13 | |||
| 2015-12-31 | $319.00M 10-K · filed 2018-02-13 | |||
| 2014-12-31 | $404.00M 10-K · filed 2017-02-14 | |||
| 2013-12-31 | $400.00M 8-K · filed 2016-10-31 | |||
| 2012-12-31 | $359.00M 10-K · filed 2015-02-19 | |||
| 2011-12-31 | $337.00M 10-K · filed 2014-02-24 | |||
| 2010-12-31 | $357.00M 10-K · filed 2013-02-27 | |||
| 2009-12-31 | $324.00M 10-K · filed 2012-02-29 | |||
| 2008-12-31 | $267.00M 10-K · filed 2011-02-25 | |||
| 2007-12-31 | $316.00M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |